Home >> Tag Archives: Seattle Genetics—

Tag Archives: Seattle Genetics—

Adcetris gets FDA nod for pcALCL

Nov. 22, 2017—The FDA granted approval to Seattle Genetics’ Adcetris (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides who have received prior systemic therapy. Approval was based on a phase-three, randomized, open-label, multicenter clinical trial (Alcanza) of brentuximab vedotin in patients with MF or pcALCL who had previously received ...

Read More »